NYSE:DVA - Davita Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $69.98 -0.59 (-0.84 %) (As of 07/20/2018 04:00 PM ET)Previous Close$70.57Today's Range$69.83 - $70.8252-Week Range$52.51 - $80.71Volume951,689 shsAverage Volume1.51 million shsMarket Capitalization$12.32 billionP/E Ratio21.08Dividend YieldN/ABeta1.1 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado. Receive DVA News and Ratings via Email Sign-up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryHealth Care Services SectorMedical SymbolNYSE:DVA CUSIP23918K10 Webwww.davita.com Phone303-405-2100 Debt Debt-to-Equity Ratio1.94 Current Ratio2.94 Quick Ratio2.90 Price-To-Earnings Trailing P/E Ratio21.08 Forward P/E Ratio17.11 P/E Growth1.03 Sales & Book Value Annual Sales$10.88 billion Price / Sales1.12 Cash Flow$7.6397 per share Price / Cash9.16 Book Value$26.66 per share Price / Book2.62 Profitability EPS (Most Recent Fiscal Year)$3.32 Net Income$663.61 million Net Margins2.94% Return on Equity13.84% Return on Assets3.61% Miscellaneous Employees74,500 Outstanding Shares174,500,000Market Cap$12,321.45 Davita (NYSE:DVA) Frequently Asked Questions What is Davita's stock symbol? Davita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA." How will Davita's stock buyback program work? Davita announced that its Board of Directors has authorized a stock buyback plan on Wednesday, October 11th 2017, which permits the company to repurchase $1,500,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company's management believes its stock is undervalued. How were Davita's earnings last quarter? Davita Inc (NYSE:DVA) posted its quarterly earnings results on Thursday, May, 3rd. The company reported $1.05 EPS for the quarter, beating analysts' consensus estimates of $0.92 by $0.13. The business had revenue of $2.85 billion for the quarter, compared to analysts' expectations of $2.79 billion. Davita had a return on equity of 13.84% and a net margin of 2.94%. Davita's revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.79 earnings per share. View Davita's Earnings History. When is Davita's next earnings date? Davita is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Davita. What price target have analysts set for DVA? 11 brokerages have issued 1-year price objectives for Davita's stock. Their predictions range from $60.00 to $97.00. On average, they expect Davita's share price to reach $81.1250 in the next year. This suggests a possible upside of 15.9% from the stock's current price. View Analyst Ratings for Davita. What is the consensus analysts' recommendation for Davita? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Davita in the last year. There are currently 4 hold ratings, 5 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Davita's key competitors? Some companies that are related to Davita include Fresenius Medical Care AG & Co. (FMS), Tivity Health (TVTY), American Renal Associates (ARA), Catasys (CATS), Caladrius Biosciences (CLBS), Pacific Health Care Organization (PFHO), BioRestorative Therapies (BRTX), MYnd Analytics (MYND), Hooper Holmes (HPHW) and American Caresource (GNOW). Who are Davita's key executives? Davita's management team includes the folowing people: Mr. Kent J. Thiry, Chairman & CEO (Age 62)Joel Ackerman, Chief Financial Officer (Age 53)Mr. James K. Hilger, Chief Accounting Officer (Age 56)Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 50)Mr. Javier J. Rodriguez, Chief Exec. Officer of DaVita Kidney Care (Age 47) Has Davita been receiving favorable news coverage? Media headlines about DVA stock have trended somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Davita earned a news impact score of 0.12 on Accern's scale. They also gave news coverage about the company an impact score of 47.08 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. Who are Davita's major shareholders? Davita's stock is owned by many different of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (1.03%), Bank of Montreal Can (0.14%), DnB Asset Management AS (0.12%), Retirement Systems of Alabama (0.09%), Calamos Advisors LLC (0.03%) and Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%). Company insiders that own Davita stock include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt, Michael David Staffieri, Pamela M Arway and William L Roper. View Institutional Ownership Trends for Davita. Which major investors are selling Davita stock? DVA stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Hartford Investment Management Co., DnB Asset Management AS, Bank of Montreal Can, Clinton Group Inc., Municipal Employees Retirement System of Michigan, Fjarde AP Fonden Fourth Swedish National Pension Fund and Boston Advisors LLC. Company insiders that have sold Davita company stock in the last year include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway and William L Roper. View Insider Buying and Selling for Davita. Which major investors are buying Davita stock? DVA stock was purchased by a variety of institutional investors in the last quarter, including Cornerstone Wealth Management LLC, Whittier Trust Co., CenturyLink Investment Management Co, Whittier Trust Co. of Nevada Inc., Denali Advisors LLC, Calamos Advisors LLC, State of Alaska Department of Revenue and Atria Investments LLC. View Insider Buying and Selling for Davita. How do I buy shares of Davita? Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Davita's stock price today? One share of DVA stock can currently be purchased for approximately $69.98. How big of a company is Davita? Davita has a market capitalization of $12.32 billion and generates $10.88 billion in revenue each year. The company earns $663.61 million in net income (profit) each year or $3.32 on an earnings per share basis. Davita employs 74,500 workers across the globe. How can I contact Davita? Davita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 303-405-2100 or via email at [email protected] MarketBeat Community Rating for Davita (NYSE DVA)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 343 (Vote Outperform)Underperform Votes: 365 (Vote Underperform)Total Votes: 708MarketBeat's community ratings are surveys of what our community members think about Davita and other stocks. Vote "Outperform" if you believe DVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: Are analyst ratings accurate?